J&J, Amgen End Clash Over Biosimilar of Lucrative Stelara (1)

Johnson & Johnson and Amgen Inc. settled a patent-infringement suit over a proposed biosimilar version of the blockbuster ulcerative colitis drug Stelara on the same day that Amgen’s response to a preliminary injunction bid was due.

Judge Maryellen Noreika on Tuesday approved the stipulation and order of dismissal in the US District Court for the District of Delaware. J&J’s Janssen Biotech Inc. unit and Amgen filed notice of the deal on Monday, mooting an already-extended deadline for Amgen to file its answer to J&J’s motion for a preliminary injunction.

The case has been closely watched as an example of how ...